JPMorgan raised the firm’s price target on iRhythm (IRTC) to $190 from $145 and keeps an Overweight rating on the shares. The company reported a sizable sales “beat-and-raise” in Q2 with better profitability, the analyst tells investors in a research note. The firm sees multiple drivers sustaining iRhythm’s acceleration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Strong Performance and Growth Potential Drive Buy Rating
- Irhythm Technologies: Strong Performance and Promising Outlook Drive Buy Rating
- iRhythm Technologies Reports Strong Q2 2025 Growth
- Closing Bell Movers: Apple up 2%, Amazon down over 6% after results
- iRhythm sees FY25 revenue $720M-$730M, consensus $695.75M